Navigation Links
Low-dose treatment may block malaria transmission
Date:11/14/2013

Lower doses of the antimalarial drug primaquine are as effective as higher doses in reducing malaria transmission, according to a study published today in Lancet Infectious Diseases by London School of Hygiene & Tropical Medicine researchers.

Primaquine is one of the few antimalarial drugs that targets the transmission stages of the malaria parasite, the gametocytes, and is therefore considered to be an important tool for malaria elimination.

However, standard doses of the drug cause reduced blood count in individuals with a deficiency in glucose-6-phosphate dehydrogenase (G6PD) enzyme. This red blood cell disorder is common in malaria endemic areas, and has therefore limited the use of primaquine in malaria programmes, and prompted the World Health Organization (WHO) to advise a reduction in dosage from 0.75 mg/kg to 0.25mg/kg. But until now, the efficacy of lower doses of primaquine had not been formally evaluated.

The study, carried out in Jinja, Uganda, treated G6PD-normal children with a conventional anti-malarial drug either on its own or with one of three different doses of primaquine. The subsequent carriage of malaria gametocytes was monitored for two weeks and safety outcomes were monitored for four weeks. Results showed that a dose of 0.4 mg/kg, approximately half of the previously recommended dose (0.75 mg/kg), was as effective at reducing the transmission potential of individuals with malaria.

These results establish that low dose primaquine is still effective and safe in a G6PD-normal population, and paves the way for using low-dose primaquine as a component of strategies to reduce malaria transmission and to stop the spread of drug-resistant malaria parasites.

The next step is to include the current WHO-recommended 0.25 mg/kg dose of primaquine in efficacy studies, and to test the safety of low dose primaquine in G6PD-deficient individuals.

Lead author Dr Chi Eziefula, Wellcome Trust clinical research fellow, said: "Until now, the use of primaquine was limited because of safety concerns, but lower doses had never been tested formally. These findings, that efficacy is retained at a lower dose, imply that primaquine could play an important role in malaria elimination programmes. We now need to evaluate the safety of low-dose primaquine in G6PD-deficient individuals. More questions remain to be answered regarding the best operational strategy for the deployment of primaquine to block malaria transmission."

Co-author Professor Chris Drakeley, Director of the London School of Hygiene & Tropical Medicine's Malaria Centre, said: "This work is a crucial step in the evaluation of primaquine as a malaria transmission blocking intervention. Further work is needed to show reduced infectivity to mosquitoes and to confirm the improved safety of these lower doses."

Professor Moses Kamya of the Infectious Disease Research Collaboration in Kampala, Uganda noted: "This study provides important contemporary information that allows malaria control programmes in endemic countries in Africa to consider the use of primaquine as part of their efforts to deal with this killer disease."


'/>"/>

Contact: Katie Steels
press@lshtm.ac.uk
44-020-792-92802
London School of Hygiene & Tropical Medicine
Source:Eurekalert

Related biology news :

1. Northeastern researchers have discovered a new treatment to cure MRSA infection
2. Wayne State researchers discover specific inhibitor for rheumatoid arthritis treatment
3. Discovery may lead to new treatments for allergic diseases
4. Research reveals new understanding, warning signs, and potential treatments for multiple sclerosis
5. Genetic aberration paves the way for new treatment of cancer disease
6. Breakthrough by Temple researchers could lead to new treatment for heart attack
7. Queens University in €6m bid to find new Cystic Fibrosis treatments
8. BUSM researchers identify molecule that could aid lung cancer detection, treatment
9. Salvianolate for treatment of cerebral ischemia-reperfusion injuries
10. UAlberta medical researchers discover potential new treatment for colitis
11. New eye treatment effective in laboratory tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2016)... , Dec. 16, 2016   IdentyTechSolutions America ... management products and solutions and a cutting-edge manufacturer ... that it is offering seamless, integrated solutions that ... entrance products. The solutions provide IdentyTech,s customers with ... their facilities from crime and theft. ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December ... leading global financial services provider, today announced an agreement with ... behavioural biometrics, to join forces. The partnership will enable clients ... strategies in compliance with local data protection regulation. ... In order to ...
(Date:12/15/2016)... Dec. 15, 2016 Advancements in ... health wellness and wellbeing (HWW), and security ... three new passenger vehicles begin to feature ... recognition, heart beat monitoring, brain wave monitoring, ... monitoring, and pulse detection. These will be ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... ... January 18, 2017 , ... Executive search ... in its continued commitment to the advancement of the clinical trials segment. Hosted ... related to clinical trial planning and management. , As executive talent specialists ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... paralysis, today announced that it has submitted a 510(k) to the FDA, requesting ... utilize MYOLYN’s patent-pending functional electrical stimulation (FES) technology. , The submission marks ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... the latest paper by its Science Editor, Dr. Elisabeth Bik, in the December ... Microbiologie). Dr. Bik joined uBiome in October 2016 from her previous position at ...
(Date:1/18/2017)...  Caris Life Sciences, a leading innovator in ... private funder of pancreatic cancer research, are collaborating ... of immunotherapy in the treatment of pancreatic cancer. ... identify potential trial candidates based on biomarker expression ... study investigators. The Lustgarten Foundation is a sponsor ...
Breaking Biology Technology: